ELEPHAS-04 (Mayo Clinic)
Multiple Solid Tumors
ObservationalActive
Key Facts
About Elephas Biosciences
Elephas Biosciences is pioneering a novel functional diagnostics platform designed to predict immunotherapy response using live tumor tissue. Its core technology, elive™, preserves the native tumor microenvironment and measures dynamic cytokine activity ex vivo to provide a more biologically relevant prediction of therapeutic efficacy than static biomarkers. The company is currently validating its platform through multiple observational clinical trials while engaging with pharmaceutical R&D, research scientists, and medical oncologists through partnership and early access models. Elephas operates as a private, pre-revenue company focused on establishing the clinical utility of its diagnostic approach.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Abexinostat + Pembrolizumab | Xynomic Pharmaceuticals | Phase 1b |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| UNO (Ultrahigh NO) | Beyond Air | Phase 1/2 |
| SonoLeukin™ | Vesselon | Pre-clinical |
| Metastasis Companion Diagnostic | Mestastop Solutions | Prospective Clinical Trials |
| Anti-metastasis Drug Discovery | Mestastop Solutions | Preclinical/Discovery |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |